Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.43 |
| ▸ | RET | P07949 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.42 |
| ▸ | HRH1 | P35367 | 6/20 | 0.42 |
| ▸ | LMNA | P02545 | 5/20 | 0.42 |
| ▸ | HTR2B | P41595 | 5/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.42 |
| ▸ | DRD2 | P14416 | 4/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.42 |
| ▸ | HTR2A | P28223 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2878604 | 1.00 | BCHE (0.44) | BCHECES1CYP3A4CYP1A2RET | |
| SCHEMBL15908322 | 0.87 | CYP3A4 (0.50) | CYP3A4CYP1A2RETCYP2C19SLC6A2 | |
| SCHEMBL653565 | 0.80 | CYP3A4 (0.63) | CES1CYP3A4CYP1A2RETCYP2C19 | |
| SCHEMBL7815467 | 0.77 | CYP1A2 (0.41) | CYP3A4CYP1A2RETCYP2C19SLC6A2 | |
| SCHEMBL11174843 | 0.75 | CES1 (0.57) | BCHECES1CYP1A2CYP2C19DRD2 | |
| SCHEMBL11174838 | 0.75 | CES1 (0.57) | BCHECES1CYP1A2CYP2C19DRD2 | |
| SCHEMBL652162 | 0.72 | HTR2B (0.68) | CYP1A2SLC6A2CHRM1HRH1LMNA | |
| SCHEMBL13051513 | 0.72 | HTR2B (0.68) | CYP1A2SLC6A2CHRM1HRH1LMNA | |
| SCHEMBL652161 | 0.72 | HTR2B (0.68) | CYP1A2SLC6A2CHRM1HRH1LMNA | |
| SCHEMBL976344 | 0.71 | CES1 (0.67) | BCHECES1CYP3A4CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2152074-A1 | COMPOSITIONS OF (-)-E-10-OH-NT AND METHODS FOR THEIR SYNTHESIS AND USE | Adolor Corporation (US) | 2010-02-17 | — | — | EP | claimed |
| WO-2008134325-A1 | COMPOSITIONS OF (-)-E-10-OH-NT AND METHODS FOR THEIR SYNTHESIS AND USE | ADOLOR CORPORATION (US) | 2008-11-06 | — | — | WO | claimed |
| US-20080275131-A1 | COMPOSITIONS OF (-)-E-10-OH-NT AND METHODS FOR THEIR SYNTHESIS AND USE | ADOLOR CORPORATION (US) | 2008-11-06 | — | — | US | claimed |
| US-9090535-B2 | Hydroxylated tricyclic compounds | NEKTAR THERAPEUTICS (US) | 2015-07-28 | — | — | US | disclosed |
| US-20120178815-A1 | Compositions of (-)-E-10-OH-NT and Methods for Their Synthesis and Use | ADOLOR CORPORATION (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2012079017-A1 | HYDROXYLATED TRICYCLIC COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2012-06-14 | — | — | WO | disclosed |
| EP-2152074-A1 | COMPOSITIONS OF (-)-E-10-OH-NT AND METHODS FOR THEIR SYNTHESIS AND USE | Adolor Corporation (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008134325-A1 | COMPOSITIONS OF (-)-E-10-OH-NT AND METHODS FOR THEIR SYNTHESIS AND USE | ADOLOR CORPORATION (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20080275131-A1 | COMPOSITIONS OF (-)-E-10-OH-NT AND METHODS FOR THEIR SYNTHESIS AND USE | ADOLOR CORPORATION (US) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178815-A1 | Compositions of (-)-E-10-OH-NT and Methods for Their Synthesis and Use | NNMT, NT5C3B, NT5E | BCHE 399/4885CES1 462/4885CYP3A4 467/4885 |
| US-20080275131-A1 | COMPOSITIONS OF (-)-E-10-OH-NT AND METHODS FOR THEIR SYNTHESIS AND USE | NNMT, NT5C3B, NT5E | BCHE 399/4885CES1 462/4885CYP3A4 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.